PIK3CA and breast cancer: PIK3CA mutations occur in around 10% of early TNBC, and their frequency increases in metastatic forms, reflecting a subset of originally ER+ breast cancer that relapse, losing their ER expression, and thus becoming “secondary” TNBC.